Condition: Systemic Lupus Erythematosus Nephritis · Sponsor: Kolding Sygehus
Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.
This description comes directly from the study's public registry record.
Rikke Z Langkilde, MD, phd · 4530281347 · rikke.zachar.langkilde@rsyd.dk
Anne D Thuesen, MD, phd, clinical lector · anne.daugaard.thuesen2@rsyd.dk
Always discuss trial participation with your own doctor first.
| Kolding Hospital | Kolding, Denmark | Not Yet Recruiting |
| Department of Nephrology | Odense, Denmark | Not Yet Recruiting |
| Department of Rheumatology | Odense, Denmark | Recruiting |
| Univesity of Southern Denmark | Odense, Denmark | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06642402